File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Epidemiological and clinical characteristics of persistent hepatitis E due to rat hepatitis E virus and genotype 4 hepatitis E virus

TitleEpidemiological and clinical characteristics of persistent hepatitis E due to rat hepatitis E virus and genotype 4 hepatitis E virus
Authors
Issue Date2020
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
The Liver Meeting Digital ExperienceTM 2020 of the American Association for the Study of Liver Diseases (AASLD), 13-16 November 2020. In Hepatology, 2020, v. 72 n. 1, Suppl., p. 621A How to Cite?
AbstractBackground: Hepatitis E virus (HEV) can cause persistent infections in immunocompromised persons. Chronic HEV infections described in the literature are usually due to genotype 3 HEV, which belongs to Orthohepevirus species A. However, the predominant HEV genotype in East Asia is genotype 4 (HEV-4). In addition, we have recently shown that rat hepatitis E (Orthohepevirus species C) is capable of infecting humans. Rat hepatitis E (HEV-C) is a highly divergent rodent virus sharing less than 60% genetic homology with HEV genotypes within species A. HEV-C1 infection is missed by most HEV diagnostic methods. We have previously shown that genotype 4 HEV and HEV-C can also cause persistent hepatitis in immunocompromised persons, but the characteristics of HEV infection in this population are uncertain. The aim of this study is to compare the epidemiological and clinical characteristics of persistent HEV-4 and HEV-C infections. Methods: This study was conducted in Hong Kong where routine HEV genotyping surveillance and diagnostic testing for HEV-C is performed. We retrieved data of hepatitis E patients from January 1, 2017 to December 31, 2019. Out of 95 eligible patients with genotyping data, we identified 70 HEV-4 and 11 HEV-C infected patients with available data. Clinical history was reviewed to identify patients with persistent HEV-4 and HEV-C infection, defined as HEV viremia for more than 3 months. Response to reduction in immunosuppression or ribavirin therapy was assessed in treated individuals. Results: The mean age of HEV-4 patients was 57.5 while that of HEV-C patients was 64 (p = 0.301). 6/11 (54.5%) HEV-C infections occurred in transplant recipients or HIV-infected persons compared to 6/70 (8.6%) HEV-4 infections (p < 0.005). Persistent infection occurred in 7/11 (63.6%) HEV-C infected patients, including one apparently immunocompetent elderly woman. All 6 HEV-4 infected transplant recipients progressed to persistent infection. None of the individuals with persistent HEV-4 or HEV-C infection spontaneously cleared viremia despite reduction of immunosuppression. Of 5 HEV-4 and 2 HEV-C infected persons receiving ribavirin, 4 had sustained virological response, while 3 were non-responders. Mortality among persistently infected individuals was 3/13 (23%), but was not directly attributable to HEV. Conclusion: Rat hepatitis E (HEV-C) and HEV genotype 4 are emerging variants capable of causing persistent hepatitis E in immunocompromised persons. HEV-C, in particular, appears to preferentially infect immunocompromised individuals who are predisposed to progress to persistent infection. Worryingly, these infections are associated with high rates of progression to persistence despite reduction of immunosuppression. Ribavirin refractory disease is not infrequent. Further research on clinical characteristics and ribavirin responsiveness of HEV-4 and HEV-C infections in immunocompromised persons is required.
DescriptionPoster Presentation - no. 1019
Persistent Identifierhttp://hdl.handle.net/10722/305093
ISSN
2023 Impact Factor: 12.9
2023 SCImago Journal Rankings: 5.011

 

DC FieldValueLanguage
dc.contributor.authorSridhar, S-
dc.contributor.authorWu, S-
dc.contributor.authorChew, NFS-
dc.contributor.authorSitu, J-
dc.contributor.authorYip, CY-
dc.date.accessioned2021-10-05T02:39:37Z-
dc.date.available2021-10-05T02:39:37Z-
dc.date.issued2020-
dc.identifier.citationThe Liver Meeting Digital ExperienceTM 2020 of the American Association for the Study of Liver Diseases (AASLD), 13-16 November 2020. In Hepatology, 2020, v. 72 n. 1, Suppl., p. 621A-
dc.identifier.issn0270-9139-
dc.identifier.urihttp://hdl.handle.net/10722/305093-
dc.descriptionPoster Presentation - no. 1019-
dc.description.abstractBackground: Hepatitis E virus (HEV) can cause persistent infections in immunocompromised persons. Chronic HEV infections described in the literature are usually due to genotype 3 HEV, which belongs to Orthohepevirus species A. However, the predominant HEV genotype in East Asia is genotype 4 (HEV-4). In addition, we have recently shown that rat hepatitis E (Orthohepevirus species C) is capable of infecting humans. Rat hepatitis E (HEV-C) is a highly divergent rodent virus sharing less than 60% genetic homology with HEV genotypes within species A. HEV-C1 infection is missed by most HEV diagnostic methods. We have previously shown that genotype 4 HEV and HEV-C can also cause persistent hepatitis in immunocompromised persons, but the characteristics of HEV infection in this population are uncertain. The aim of this study is to compare the epidemiological and clinical characteristics of persistent HEV-4 and HEV-C infections. Methods: This study was conducted in Hong Kong where routine HEV genotyping surveillance and diagnostic testing for HEV-C is performed. We retrieved data of hepatitis E patients from January 1, 2017 to December 31, 2019. Out of 95 eligible patients with genotyping data, we identified 70 HEV-4 and 11 HEV-C infected patients with available data. Clinical history was reviewed to identify patients with persistent HEV-4 and HEV-C infection, defined as HEV viremia for more than 3 months. Response to reduction in immunosuppression or ribavirin therapy was assessed in treated individuals. Results: The mean age of HEV-4 patients was 57.5 while that of HEV-C patients was 64 (p = 0.301). 6/11 (54.5%) HEV-C infections occurred in transplant recipients or HIV-infected persons compared to 6/70 (8.6%) HEV-4 infections (p < 0.005). Persistent infection occurred in 7/11 (63.6%) HEV-C infected patients, including one apparently immunocompetent elderly woman. All 6 HEV-4 infected transplant recipients progressed to persistent infection. None of the individuals with persistent HEV-4 or HEV-C infection spontaneously cleared viremia despite reduction of immunosuppression. Of 5 HEV-4 and 2 HEV-C infected persons receiving ribavirin, 4 had sustained virological response, while 3 were non-responders. Mortality among persistently infected individuals was 3/13 (23%), but was not directly attributable to HEV. Conclusion: Rat hepatitis E (HEV-C) and HEV genotype 4 are emerging variants capable of causing persistent hepatitis E in immunocompromised persons. HEV-C, in particular, appears to preferentially infect immunocompromised individuals who are predisposed to progress to persistent infection. Worryingly, these infections are associated with high rates of progression to persistence despite reduction of immunosuppression. Ribavirin refractory disease is not infrequent. Further research on clinical characteristics and ribavirin responsiveness of HEV-4 and HEV-C infections in immunocompromised persons is required.-
dc.languageeng-
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/-
dc.relation.ispartofHepatology-
dc.relation.ispartofThe Liver Meeting Digital ExperienceTM 2020 of the American Association for the Study of Liver Diseases (AASLD)-
dc.titleEpidemiological and clinical characteristics of persistent hepatitis E due to rat hepatitis E virus and genotype 4 hepatitis E virus-
dc.typeConference_Paper-
dc.identifier.emailSridhar, S: sid8998@hku.hk-
dc.identifier.emailWu, S: wss2017@hku.hk-
dc.identifier.emailChew, NFS: chewnf@hku.hk-
dc.identifier.emailSitu, J: situjw@hku.hk-
dc.identifier.emailYip, CY: yipcyril@hku.hk-
dc.identifier.authoritySridhar, S=rp02249-
dc.identifier.authorityYip, CY=rp01721-
dc.description.natureabstract-
dc.identifier.doi10.1002/hep.31579-
dc.identifier.hkuros326235-
dc.identifier.volume72-
dc.identifier.issue1, Suppl.-
dc.identifier.spage621A-
dc.identifier.epage621A-
dc.publisher.placeUnited States-
dc.identifier.partofdoi10.1002/hep.31579-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats